KR950005838A - 코티코스테로이드 17- 알킬 카보네이트21-[0]-카복실산 및 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제 - Google Patents
코티코스테로이드 17- 알킬 카보네이트21-[0]-카복실산 및 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제 Download PDFInfo
- Publication number
- KR950005838A KR950005838A KR1019940021252A KR19940021252A KR950005838A KR 950005838 A KR950005838 A KR 950005838A KR 1019940021252 A KR1019940021252 A KR 1019940021252A KR 19940021252 A KR19940021252 A KR 19940021252A KR 950005838 A KR950005838 A KR 950005838A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- carboxylic acid
- compound
- iii
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 10
- 150000001733 carboxylic acid esters Chemical class 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title claims 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 5
- 239000003470 adrenal cortex hormone Substances 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract 3
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 239000000460 chlorine Chemical group 0.000 claims 4
- 239000011737 fluorine Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- -1 unsubstituted Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims 2
- CFGDUGSIBUXRMR-UHFFFAOYSA-N 1,2-dihydropyrrol-2-ide Chemical compound C=1C=[C-]NC=1 CFGDUGSIBUXRMR-UHFFFAOYSA-N 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 일반식(Ⅰ)의 코티코이드 17-알킬 카보네이트 21-카복실산 및 카본산 에스테르를 기술하고 있다.
상기식에서, A는 CHOH 및 CHCl, CH2, C=0 또는 9(11) 이중결합이고; Y는 H, F 또는 Cl이고; Z는 H, F 또는 CH3이고; R(1)은 아릴 또는 헤트아릴이고; n 및 m은 0 또는 1이고; R(2)는 알킬 또는 -(CH2)2-OCH3이고; R(3)은 H 또는 메틸이다.
이는 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 활성화 카복실산과 반응시킴으로써 수득한다.
R(6)-CO(O)n-[(C1-C4)-alkyl]m-R(1) (Ⅲ)
상기식에서, R(5)는 OH이다.
일반식(Ⅰ)의 화합물은 매우 강한 국부성 항염증작용을 갖고 매우 우수한 비율로 국부 대 전신의 항염증효과를 나타내며, 이 비율은 종종 21-에스테르 라디칼에 어떠한 아릴 또는 헤트아릴 그룹을 함유하지 않은 동족의 코티코이드 17-알킬 카보네이트 21-에스테르보다 현저하게 뛰어나다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 일반식(Ⅰ)의 코티코이드 17-알킬 카보네이트 21-카복실산 또는 카본산 에스테르.상기식에서, A는 임의의 입체 배열의 CHOH 및 CHCl이거나, CH2, C=0 또는 9(11) 이중결합이고, Y는 수소, 불소 또는 염소이고, Z는 수소, 불소 또는 메틸이고, R(1)은 임의로 치환되거나 융합된 아릴 또는 헤트아릴이고, (C1-C4)-알킬은 포화되거나, 1회 이상 불포화되거나, 추가로 알킬 그룹에 의해 측쇄되거나, 비치환되거나, 또는 헤테로원자, O, S 또는 N으로 삽입 되는 치환되고, n은 0 또는 1이고, m은 0 또는 1이고, R(2)는 선형 또는 측쇄 (C1-C8)-알킬 또는 -(CH2)2-OCH3이고, R(3)은 H 또는 α-, 또는 β-메틸이다.
- 제 1항에 있어서, R(1), A, Y, Z, R(3) 및 R(4)가 제 1항에서 정의한 바와 같고 R(2)가 선형 또는 측쇄 (C1-C5)-알킬 또는 -(CH2)2-OCH3인 일반식(Ⅰ)의 코티코이드 17-알킬 카보네이트 21-카복실산 또는 카본산 에스테르.
- a) R(5)가 OH인 일반식(Ⅱ)의 화합물을, 수분 제거제(DCCI 등)의 존재하에, a1) n이 0이고 m이 0또는 1이고 R(6)이 Cl, Br, O[-CO-(O)n-[[(C1-C4)-알킬]m-R(1)]1, -OC(O)CF3또는 기타의 활성화 산 라디칼 일반식(Ⅲ)의 활성화 카복실산, 바람직하게는 할로겐화물 또는 무수물 또는 아졸라이드와 반응시키거나, a2) n이 1이고 m이 0 또는 1이고 R(6)이 Cl, Br 또는 I인 일반식(Ⅲ)의 할로포르메이트와 반응시키거나, a3) n이 0이고 R(6)이 OH인 일반식(Ⅲ)의 카복실산 그 자체와 반응시키거나, b) R(5)가 Br, I 또는 설폰산 아릴 또는 알킬 에스테르 그룹인 일반식(Ⅱ)의 화합물을 n이 0이고 R(6)이 -[O-Me+]이고 Me가 바람직하게는 알칼리 금속염의 양이온 또는 트리알킬암모늄염의 양이온인 일반식(Ⅲ)의 카복실산의 염, 바람직하게는 K 또는 Na염, 또는 트리알킬암모늄염과 반응시킴을 특징으로 하여, 제 1항에 따르는 일반식(Ⅰ)의 화합물을 제조하는 방법.R(6)-CO(O)n-[(C1-C4)-alkyl]m-R(1) (Ⅲ)상기식에서, A는 임의의 입체 배열의 CHOh 및 CHCl이거나, CH2, C=0 또는 9(11) 이중결합이고, Y는 수소, 불소 또는 염소이고, Z는 수소, 불소 또는 메틸이고, R(1)은 임의로 치환되거나 융합된 아릴 또는 헤트아릴이고, (C1-C4)-알킬은 포화되거나, 1회 이상 불포화되거나, 추가로 알킬 그룹에 의해 측쇄되거나, 비치환되거나, 또는 헤테로원자 O, S 또는 N으로 삽입 또는 치환되고, n은 0 또는 1이고, m은 0 또는 1이고, R(2)는 선형 또는 측쇄 (C1-C8)-알킬 또는 -(CH2)2-OCH3이고, R(3)은 수소 또는 α-, 또는 β-메틸이다.
- 제 1항에서 청구한 일반식(Ⅰ)의 화합물 유효량을 함유하는, 특히 염증성 및 알레르기성 피부염 치료용 약제.
- 제 1항에서 청구한 일반식(Ⅰ)의 화합물 유효량을 통상적인 약제학적 보조물질과 혼합하여, 감염된 피부부위에 적용하여 피부병을 치료하는 방법.
- 피부병 치료용 약제를 제조하기 위한, 제 1항에서 청구한 일반식(Ⅰ)의 화합물의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4328819.7 | 1993-08-27 | ||
| DE4328819A DE4328819A1 (de) | 1993-08-27 | 1993-08-27 | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950005838A true KR950005838A (ko) | 1995-03-20 |
Family
ID=6496144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940021252A KR950005838A (ko) | 1993-08-27 | 1994-08-27 | 코티코스테로이드 17- 알킬 카보네이트21-[0]-카복실산 및 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5608093A (ko) |
| EP (1) | EP0640616B1 (ko) |
| JP (1) | JP3780007B2 (ko) |
| KR (1) | KR950005838A (ko) |
| CN (1) | CN1062562C (ko) |
| AT (1) | ATE228530T1 (ko) |
| AU (1) | AU674980B2 (ko) |
| CA (1) | CA2130943C (ko) |
| DE (2) | DE4328819A1 (ko) |
| DK (1) | DK0640616T3 (ko) |
| ES (1) | ES2187513T3 (ko) |
| FI (1) | FI113871B (ko) |
| HU (1) | HU217620B (ko) |
| IL (1) | IL110798A (ko) |
| NO (1) | NO304987B1 (ko) |
| PT (1) | PT640616E (ko) |
| TW (1) | TW320634B (ko) |
| ZA (1) | ZA946508B (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100472303B1 (ko) * | 2002-05-21 | 2005-03-08 | 김영미 | 결장표적성 프로드럭으로서의 코티코스테로이드21-설페이트 소듐 유도체 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043256A (en) * | 1996-09-16 | 2000-03-28 | Grassetti; Davide R. | Antimutagenic agents |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| BR0209271A (pt) * | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
| US20040248867A1 (en) * | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| US8729108B2 (en) * | 2008-06-17 | 2014-05-20 | Christopher J Dannaker | Waterborne topical compositions for the delivery of active ingredients such as azelaic acid |
| EP2435462A1 (en) * | 2009-05-29 | 2012-04-04 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| CN109320575B (zh) * | 2018-04-22 | 2021-02-12 | 吉林大学 | 拟人参皂苷12-酮-pf11及提取方法及其医药用途 |
| WO2023088308A1 (zh) * | 2021-11-16 | 2023-05-25 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
| US4242344A (en) * | 1979-01-22 | 1980-12-30 | Merck & Co., Inc. | Piperazinyl-imidazo[1,2-a]pyrazines |
| IL66432A0 (en) * | 1981-08-04 | 1982-12-31 | Plurichemie Anstalt | Process for the preparation of steroidal esters |
| CA1310009C (en) * | 1984-03-28 | 1992-11-10 | John Mark Braughler | Ester prodrugs of steroids |
| US4948533A (en) * | 1984-03-28 | 1990-08-14 | The Upjohn Company | 11a-hydroxy steroid diester |
| DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
-
1993
- 1993-08-27 DE DE4328819A patent/DE4328819A1/de not_active Withdrawn
-
1994
- 1994-02-28 TW TW083101669A patent/TW320634B/zh active
- 1994-08-22 PT PT94113048T patent/PT640616E/pt unknown
- 1994-08-22 DE DE59410210T patent/DE59410210D1/de not_active Expired - Lifetime
- 1994-08-22 DK DK94113048T patent/DK0640616T3/da active
- 1994-08-22 EP EP94113048A patent/EP0640616B1/de not_active Expired - Lifetime
- 1994-08-22 ES ES94113048T patent/ES2187513T3/es not_active Expired - Lifetime
- 1994-08-22 AT AT94113048T patent/ATE228530T1/de active
- 1994-08-25 US US08/294,804 patent/US5608093A/en not_active Expired - Lifetime
- 1994-08-25 HU HU9402451A patent/HU217620B/hu not_active IP Right Cessation
- 1994-08-25 FI FI943902A patent/FI113871B/fi not_active IP Right Cessation
- 1994-08-25 AU AU71474/94A patent/AU674980B2/en not_active Expired
- 1994-08-25 CN CN94115711A patent/CN1062562C/zh not_active Expired - Fee Related
- 1994-08-26 JP JP22396394A patent/JP3780007B2/ja not_active Expired - Lifetime
- 1994-08-26 CA CA002130943A patent/CA2130943C/en not_active Expired - Lifetime
- 1994-08-26 ZA ZA946508A patent/ZA946508B/xx unknown
- 1994-08-26 NO NO943174A patent/NO304987B1/no not_active IP Right Cessation
- 1994-08-27 KR KR1019940021252A patent/KR950005838A/ko not_active Application Discontinuation
- 1994-08-28 IL IL11079894A patent/IL110798A/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100472303B1 (ko) * | 2002-05-21 | 2005-03-08 | 김영미 | 결장표적성 프로드럭으로서의 코티코스테로이드21-설페이트 소듐 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE228530T1 (de) | 2002-12-15 |
| AU674980B2 (en) | 1997-01-16 |
| TW320634B (ko) | 1997-11-21 |
| CN1062562C (zh) | 2001-02-28 |
| CA2130943C (en) | 2007-07-03 |
| HU9402451D0 (en) | 1994-10-28 |
| DK0640616T3 (da) | 2003-03-24 |
| EP0640616A3 (de) | 1995-06-28 |
| EP0640616B1 (de) | 2002-11-27 |
| FI943902A (fi) | 1995-02-28 |
| CA2130943A1 (en) | 1995-02-28 |
| NO943174L (no) | 1995-02-28 |
| IL110798A (en) | 2000-12-06 |
| NO943174D0 (no) | 1994-08-26 |
| CN1105368A (zh) | 1995-07-19 |
| ZA946508B (en) | 1995-03-28 |
| FI113871B (fi) | 2004-06-30 |
| AU7147494A (en) | 1995-03-09 |
| US5608093A (en) | 1997-03-04 |
| HUT67959A (en) | 1995-05-29 |
| EP0640616A2 (de) | 1995-03-01 |
| ES2187513T3 (es) | 2003-06-16 |
| FI943902A0 (fi) | 1994-08-25 |
| IL110798A0 (en) | 1994-11-11 |
| HU217620B (hu) | 2000-03-28 |
| DE4328819A1 (de) | 1995-03-02 |
| JPH0789982A (ja) | 1995-04-04 |
| NO304987B1 (no) | 1999-03-15 |
| PT640616E (pt) | 2003-04-30 |
| DE59410210D1 (de) | 2003-01-09 |
| JP3780007B2 (ja) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950005838A (ko) | 코티코스테로이드 17- 알킬 카보네이트21-[0]-카복실산 및 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제 | |
| KR950011463A (ko) | 코티코이드-17,21-디카복실산 에스테르 및 코티코스테로이드 17- 카복실산 에스테르 21- 카본산 에스테르, 이들의 제조방법 및 이들 화합물을 함유하는 약제 | |
| JPS6069019A (ja) | 局所抗炎症用薬剤組成物 | |
| CH628356A5 (de) | Verfahren zur herstellung neuer androstadien-17-carbonsaeureester. | |
| EP0030377A1 (de) | 9-Chlor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel | |
| EP0002234B1 (de) | Neue Prostacyclinderivate, ihre Herstellung und Anwendung | |
| EP0051558B1 (de) | Prostacyclinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| US3691214A (en) | 17-valerate ester of 6alpha,9alpha-difluoroprednisolone,its compositions and use as an anti-inflammatory agent | |
| DE2047105B2 (de) | 17-Chlorsteroide und Verfahren zu ihrer Herstellung | |
| JPS5837320B2 (ja) | プレグナンサンユウドウタイ ノ セイホウ | |
| CA2011282A1 (en) | Steroid diols, pharmaceutical compositions containing them and process for preparing same | |
| US4599330A (en) | Method of treating milk fever | |
| EP0051557B1 (de) | 5-Cyan-prostacyclinderivate, Verfahren zu ihrer Herstellung und ihrer Verwendung als Arzneimittel | |
| IE45305B1 (en) | New corticoids | |
| EP0051597B1 (de) | Neue prostacyclinderivate und ihre herstellung | |
| CH625254A5 (ko) | ||
| KR800000405B1 (ko) | D-호모스테로이드의 제조방법 | |
| GB1589585A (en) | 12a-halocorticoids | |
| US3415855A (en) | Trichloro pregnadienes and esters thereof | |
| DE1443176A1 (de) | 6 alpha-Fluor-16-beta-methyl-4-pregnene und -1,4-pregnadiene und Verfahren zu ihrer Herstellung | |
| KR800000406B1 (ko) | D-호모스테로이드의 제조방법 | |
| AP141A (en) | Novel steroid doils. | |
| CH616435A5 (ko) | ||
| CS208495B2 (en) | Method of making the alcyesters of the 4-halogen-3-oxo-androsta-1,4-dien beta-carboxyle acid | |
| DE2210697A1 (de) | Neue prostaglandinanaloga und verfahren zur herstellung derselben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |